Transaction with Affiliate Company
Samsung Electronics Co., Ltd. (KS005930, KS005935, SMSN, SMSD) ("SEC") today announced that its Board of Directors has authorized the following related-party transaction with an affiliated company.
Participation in rights offering
- Participation in the new stock issuance of Samsung Biologics ("SB")
□ Major transaction terms
|
Transaction items |
1,380,477 common shares of SB |
|
Transaction date |
April 8, 2022 |
|
Transaction value |
KRW 882.125 billion (total invested capital of KRW 1,325.318 billion) |
|
Purpose of transaction |
To purchase new shares issued by SB allotted to existing shareholders |
|
Terms and conditions |
* The transaction date is the subscription end date for existing shareholders. * The transaction value is based on the issue price per share in SB's new capital issue disclosure on February 25, 2022. * The total invested capital is SEC's cumulative investment in SB, including the transaction set forth herein. * The terms above are subject to changes in the process of SB's capital increase process. |
Other Information:
ž Number of Independent Directors present at the Board of Directors meeting: 6
ž Attendance of Audit Committee: Y
※ This disclosure is in accordance with the Korean Fair Trade Act, which mandates that a company must disclose financial and real estate transactions in the event the value of such a transaction is greater or equal to KRW 5 billion and the counterparty is an affiliate of the party required to make the disclosure.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
